Help Ensure the Safe Use of Secondary Hyperparathyroid Meds

February 2018

The new med etelcalcetide (Parsabiv, PAR-sah-biv) will raise questions about treating hyperparathyroidism in dialysis patients.

Hyperphosphatemia and low vitamin D in renal patients leads to hypocalcemia...which stimulates parathyroid hormone (PTH) release.

This is why the first steps in treating patients with elevated PTH are to control high phosphate and treat vitamin D deficiency.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote